Decreased Prostate Cancer-Specific Survival of Men with<i>BRCA</i>2 Mutations from Multiple Breast Cancer Families
Heather Thorne(University of Melbourne), Damien Bolton(University of Melbourne), Ivan Hoh(The University of Melbourne), Eveline Niedermayr(Peter MacCallum Cancer Centre), Stephen B. Fox(Peter MacCallum Cancer Centre), Jason Li, Amber J. Willems(The University of Melbourne), David Clouston(TissuPath), Gillian Mitchell(Peter MacCallum Cancer Centre), John L. Hopper(The University of Melbourne)
Cited by 112
Related Papers
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
|Journal of Clinical Oncology|2012|1.2k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k